Hyperresponsiveness of platelets in ischemic stroke

Summary

Platelet activation and aggregation are critical in the pathogenesis of acute ischemic cerebrovascular diseases. The aim of our study was to characterize platelet function in patients with acute ischemic stroke or transient ischemic attack (TIA), and to evaluate the effect of platelet activation on clinical outcome. One hundred thirty-eight consecutive patients with TIA (n=74) or stroke (n=64) were enrolled in this study. Platelet aggregation in response to ADP, epinephrine, arachidonic acid, or collagen, and expression of platelet activation receptors (CD62P, CD63, LIBS-1 and PAC-1) in the acute phase and at three months follow-up were evaluated. Platelets derived from stroke patients were more hyperaggregable in response to agonists in the acute phase compared to TIA patients (p[ADP]=0.002, p[arachidonic acid]=0.047, p[epinephrine]=0.020). Platelet activation was enhanced in the acute phase irrespective of the severity of the disease (stroke or TIA) and returned to baseline levels three months later. Persistent elevated platelet activation at three months follow-up (PAC-1) was associated with increased incidence of recurrent stroke (median, [interquartile range] 3.4, [3.0–5.2] versus 2.9, [2.3–4.0], p=0.048). In conclusion, platelets are hyperactive in acute stroke compared with TIA. A more intensified dual antiplatelet therapy may be of benefit for stroke patients.

Keywords

Stroke - transient ischemic attack - platelet activation - platelet aggregation - flow cytometry

^* These authors contributed equally to this study.

• References

• 1 Warlow CP. Epidemiology of stroke. Lancet 1998; 352 (Suppl. 03) Suppl S1-4.
• 2 Ruggeri ZM. Platelets in atherothrombosis. Nat Med 2002; 8: 1227-1234.
• 3 Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest 2005; 115: 3378-3384.
• 4 Grau AJ, Ruf A, Vogt A. et al. Increased fraction of circulating activated platelets in acute and previous cerebrovascular ischemia. Thromb Haemost 1998; 80: 298-301.
• 5 Zeller JA, Tschoepe D, Kessler C. Circulating platelets show increased activation in patients with acute cerebral ischemia. Thromb Haemost 1999; 81: 373-377.
• 6 Marquardt L, Ruf A, Mansmann U. et al. Course of platelet activation markers after ischemic stroke. Stroke 2002; 33: 2570-2574.
• 7 Zeller JA, Frahm K, Baron R. et al. Platelet-leukocyte interaction and platelet activation in migraine: A link to ischemic stroke?. J Neurol Neurosurg Psychiatry 2004; 75: 984-987.
• 8 Zeller JA, Lenz A, Eschenfelder CC. et al. Plateletleukocyte interaction and platelet activation in acute stroke with and without preceding infection. Arterioscler Thromb Vasc Biol 2005; 25: 1519-1523.
• 9 van Kooten F, Ciabattoni G, Patrono C. et al. Role of platelet activation in dementia. Haemostasis 1998; 28: 202-208.
• 10 van Kooten F, Ciabattoni G, Koudstaal PJ. et al. Increased platelet activation in the chronic phase after cerebral ischemia and intracerebral hemorrhage. Stroke 1999; 30: 546-549.
• 11 Yip HK, Liou CW, Chang HW. et al. Link between platelet activity and outcomes after an ischemic stroke. Cerebrovasc Dis 2005; 20: 120-128.
• 12 Gurbel PA, Bliden KP, Hiatt BL. et al. Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107: 2908-2913.
• 13 Muir KW, Weir CJ, Murray GD. et al. Comparison of neurological scales and scoring systems for acute stroke prognosis. Stroke 1996; 27: 1817-1820.
• 14 Brott T, Adams Jr. HP, Olinger CP. et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke 1989; 20: 864-870.
• 15 Massberg S, Mueller I, Besta F. et al. Effects of 2 different antiplatelet regimens with abciximab or tirofiban on platelet function in patients undergoing coronary stenting. Am Heart J 2003; 146: E19.
• 16 Müller I, Besta F, Schulz C. et al. Effects of statins on platelet inhibition by a high loading dose of clopidogrel. Circulation 2003; 108: 2195-2197.
• 17 Müller I, Besta F, Schulz C. et al. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 2003; 89: 783-787.
• 18 Ruf A, Pick M, Deutsch V. et al. In-vivo platelet activation correlates with red cell anionic phospholipid exposure in patients with beta-thalassaemia major. Br J Haematol 1997; 98: 51-56.
• 19 Gawaz M, Neumann FJ, Schömig A. Evaluation of platelet membrane glycoproteins in coronary artery disease: Consequences for diagnosis and therapy. Circulation 1999; 99: E1-E11.
• 20 Uchiyama S, Yamazaki M, Hara Y. et al. Alterations of platelet, coagulation, and fibrinolysis markers in patients with acute ischemic stroke. Semin Thromb Hemost 1997; 23: 535-541.
• 21 Smith NM, Pathansali R, Bath PM. Platelets and stroke. Vasc Med 1999; 4: 165-172.
• 22 Serebruany VL, Malinin AI, Ziai W. et al. Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in patients after recent ischemic stroke: For the plavix use for treatment of stroke (pluto-stroke) trial. Stroke 2005; 36: 2289-2292.
• 23 Diener HC, Bogousslavsky J, Brass LM. et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (match): Randomised, double-blind, placebo-controlled trial. Lancet 2004; 364: 331-337.
• 24 Bhatt DL, Topol EJ. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and highrisk primary prevention: Rationale and design of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance (charisma) trial. Am Heart J 2004; 148: 263-268.
• 25 Giles MF. the short and long term Rothwell. Prediction and prevention of stroke after transient ischemic attack in Expert Review of Neurotherapeutics. Future drugs 2006; 6: 381-395.
• 26 Fateh-Moghadam S, Plockinger U, Cabeza N. et al. Prevalence of aspirin resistance in patients with type 2 diabetes. Acta Diabetol 2005; 42: 99-103.